Generics
Novo Nordisk and Teva Pharmaceuticals USA reach settlement on Victoza US patent litigation case
20 March 2019 -

Denmark-based Novo Nordisk announced today that a settlement between Novo Nordisk and Teva Pharmaceuticals USA Inc has been made in the United States patent litigation case for Victoza (liraglutide).

As a result, Teva is licensed to introduce a generic version of Victoza effective 22 December 2023.

Under certain circumstances Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza on the market. If Novo Nordisk is granted six months paediatric extension for Victoza, all above-mentioned timelines will be extended by six months. All other terms of the contract are confidential. The contract is subject to review by the US Federal Trade Commission and the US Department of Justice.

Login
Username:

Password: